p38 MAPK Inhibitor SB203580 Enhances Anticancer Activity of PARP Inhibitor Olaparib in a Synergistic Way on Non-Small Cell Lung Carcinoma A549 Cells

By
Jamie Kang
-
0
224
Researchers explored the potential synergistic anticancer activities of olaparib combined with p38 mitogen-activated protein kinases (MAPK) inhibitor SB203580 on NSCLC, A549 cells.
[Biochemical And Biophysical Research Communications]
Abstract